6 Results for "

ESR1 Y537S

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "ESR1 Y537S" in MCE Product Catalog:

6
6 Cited Publications
Cat. No.: HY-109176
CAS No.: 1953133-47-5
Purity:  99.52%
Synonyms: GDC-9545; RG6171
Target:  

Estrogen Receptor/ERR

Research Areas:  

Endocrinology Cancer

Giredestrant (GDC-9545) is an orally active, full, selective Estrogen receptor α (ERα) degrader and antagonist with a DC50 of 0.03 nM. Giredestrant promotes the degradation of ERα protein, including the ESR1 Y537S mutant ERα. Giredestrant reduces uterine wet weight in immature rats and induces a low cuboidal phenotype in their endometrial epithelium. Giredestrant induces tumor regression in both ESR1 Y537S mutant and wild-type ERα tumor models. Giredestrant can be used for the research of ER + breast cancer [1].
loading...
    loading...
Cat. No.: HY-135903
CAS No.: 2407529-33-1
Synonyms: GDC-9545 tartrate; RG6171 tartrate
Target:  

Estrogen Receptor/ERR

Giredestrant tartrate (GDC-9545 tartrate) is an orally active, full, selective Estrogen receptor α (ERα) degrader and antagonist with a DC50 of 0.03 nM. Giredestrant tartrate promotes the degradation of ERα protein, including the ESR1 Y537S mutant ERα. Giredestrant tartrate reduces uterine wet weight in immature rats and induces a low cuboidal phenotype in their endometrial epithelium. Giredestrant tartrate induces tumor regression in both ESR1 Y537S mutant and wild-type ERα tumor models. Giredestrant tartrate can be used for the research of ER + breast cancer [1].
loading...
    loading...
Cat. No.: HY-164924
CAS No.: 3026007-23-5
Research Areas:  

Cancer

ERD-12310A is an orally active ERα PROTAC degrader, with a Ki value of 0.95 nM against human ERα and a DC50 of 47 pM for ERα in MCF-7 cells. ERD-12310A forms a ternary complex with ERα and the CRBN E3 ubiquitin ligase, thereby inducing ubiquitination and proteasomal degradation of wild-type and ESR1 Y537S mutant ERα. ERD-12310A induces tumor regression in ER+ breast cancer xenografts and inhibits tumor growth in ESR1 Y537S mutant breast cancer xenografts. ERD-12310A can be used in studies related to ER-positive breast cancer and ESR1-mutant breast cancer [1] .
loading...
    loading...
Cat. No.: HY-109176R
CAS No.: 1953133-47-5
Synonyms: GDC-9545 (Standard); RG6171 (Standard)
Giredestrant (Standard) (GDC-9545 (Standard); RG6171 (Standard)) is the analytical standard of Giredestrant (HY-109176). This product is intended for research and analytical applications. Giredestrant (GDC-9545) is an orally active, full, selective Estrogen receptor α (ERα) degrader and antagonist with a DC50 of 0.03 nM. Giredestrant promotes the degradation of ERα protein, including the ESR1 Y537S mutant ERα. Giredestrant reduces uterine wet weight in immature rats and induces a low cuboidal phenotype in their endometrial epithelium. Giredestrant induces tumor regression in both ESR1 Y537S mutant and wild-type ERα tumor models. Giredestrant can be used for the research of ER + breast cancer [1].
loading...
    loading...
Cat. No.: HY-101119
CAS No.: 2077980-80-2
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

GLL398 is a potent, orally bioavailable selective estrogen receptor degrader (SERD) with an IC50 value of 1.14 nM. GLL398 shows a strong dose-dependent binding to ER with a mutation at Y537S (IC50=29.5 nM). GLL398 blocks tumor growth in xenograft models of breast cancer.
loading...
    loading...
Cat. No.: HY-183804
CAS No.: 2847829-86-9
Research Areas:  

Cancer

PROTAC ER Degrader-16 is an orally active ERα PROTAC degrader with a DC50 of 1.4 nM and an IC50 of 1.9 nM. PROTAC ER Degrader-16 inhibits ER-dependent breast cancer cell proliferation and exerts anti-tumor effects in mouse models. PROTAC ER Degrader-16 can be used for breast cancer research .
loading...
    loading...